<DOC>
	<DOCNO>NCT02518750</DOCNO>
	<brief_summary>This phase-II study evaluate efficacy salvage regimen child relapse T-cell ALL lymphoma . Peg-asparaginase , mitoxantrone , intrathecal triple ( IT ) ( intrathecal methotrexate/hydrocortisone/cytarabine ) ( ITMHA ) dexamethasone commonly use drug treat relapse refractory acute lymphocytic leukemia lymphoma ( ALL ) . In study , investigator want know add three drug call panobinostat , bortezomib liposomal vincristine ( VSLI ) regimen result remission ( sign symptom leukemia lymphoma ) . - Panobinostat approve FDA treat adult multiple myeloma , approve use child give together drug use study . It widely study child . - VSLI approve FDA adult relapse refractory ALL , yet approve treat child leukemia lymphoma . - Bortezomib approve FDA treat adult cancer call multiple myeloma adult relapse mantle cell lymphoma ; approve treat child . PRIMARY OBJECTIVE : - To estimate complete remission ( CR ) rate patient T-cell lymphoblastic leukemia lymphoma first relapse . SECONDARY OBJECTIVES : - To evaluate minimal residual disease ( MRD ) level end block therapy . - To describe toxicity vincristine sulfate liposome injection ( VSLI ) use combination chemotherapy bortezomib .</brief_summary>
	<brief_title>Re-Induction Therapy Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia Lymphoma</brief_title>
	<detailed_description>This study re-induction therapy comprise three block multi-agent chemotherapy . CR evaluate follow block therapy . All patient candidate hematopoietic stem cell transplant ( HSCT ) achieve negative minimal residual disease ( MRD ) . If patient proceed HSCT follow Block A , continue therapy Block B Block C ready HSCT . Three Block Induction : Block A : approximately 5 week - Dexamethasone 10 mg/m^2/day orally ( PO ) Days 1-8 , 15-22 ( Total 16 day ) - Panobinostat 24 mg/m^2/dose PO Day 2,4,6 - Liposomal vincristine ( VSLI ) 2.25 mg/m^2 cap intravenously ( IV ) Days 7 , 14 , 21 , 28 - Mitoxantrone 10 mg/m^2 IV Day 7,14 ( In absence peripheral blast , Day 14 Mitoxantrone give WBC ≥1000 ANC ≥300 ) - Peg-asparaginase 2500 units/m^2 Days 9,23 - Bortezomib 1.3 mg/m^2 IV Days 16 , 19 , 23 , 26 - Intrathecal Triples ( IT ) ( intrathecal methotrexate/hydrocortisone/cytarabine ) ( ITMHA ) Days 1 , 7 , 14 , 21 , 28 . Additional ITs Days 10 17 patient central nervous system ( CNS ) 2 , 3 traumatic tap blast Block B : approximately 5 week - High-dose methotrexate 8 g/m^2 IV 24 hour ( give patient prior cranial irradiation ) Day 1 - 6-mercaptopurine 50 mg/m^2 PO day 1-14 - ITMHA Day 1 - High-dose cytarabine 3 g/m^2 IV every 12 hour ( Q12H ) Days 15 16 Block C : approximately 3 week - Nelarabine 650 mg/m^2/day IV Days 1-5 ( Clofarabine 40 mg/m^2/day IV Days 1-5 give instead nelarabine patient B-lymphoblastic leukemia lymphoma stratum II ) - Cyclophosphamide 300 mg/m^2 IV Days 1-5 - Etoposide 100 mg/m^2/day IV Days 1-5 Response evaluation perform end treatment block . All patient proceed hematopoietic stem cell transplantation ( HSCT ) achieve negative minimal residual disease ( MRD ) suitable donor identify . Patients could continue Block B Block C ready HSCT . If completion Block C , MRD persistently positive , plan discuss principal investigator co-principal investigator transplant team . Enrollment ongoing natural killer ( NK ) cell study consider . For patient require second transplant , HAP3R ( another clinical trial St. Jude Children 's Research Hospital ) may option . Donor select accord institutional practice transplant regimen use accord institutional HSCT protocol guideline .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , B-Cell</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Participants must relapse refractory acute lymphoblastic leukemia lymphoma ( ALL ) : Stratum I : Tcell lymphoblastic leukemia lymphoma first relapse refractory one two course frontline induction therapy . Stratum II : Bcell Tcell lymphoblastic leukemia lymphoma second third relapse refractory 2 3 induction reinduction attempt . Patients Ph+ ALL must refractory relapsed treatment regimen include tyrosine kinase inhibitor ( TKI ) . Relapse ALL define reappearance ( patient previously achieve remission ) leukemic blast bone marrow . Should flow cytometric analysis suggest relapse ( reappearance similar immunophenotype original leukemia ) presence &lt; 5 % blast morphologically , repeat bone marrow test recommend confirm relapse . Molecular genetic relapse characterize reappearance cytogenetic molecular abnormality . Age ≤ 21 year ( participant yet reach 22nd birthday ) . Able swallow capsule . Karnofsky Lansky performance score ≥ 60 % . The Lansky performance score use participant &lt; 16 year Karnofsky performance score participant ≥ 16 year . Prior therapy : There wait period participant relapse receive therapy free side effect attributable therapy . Emergent radiation therapy , one dose intrathecal chemotherapy 7 day steroid hydroxyurea permit start treatment participant relapse completion frontline therapy . Other circumstance must clear PI medical designee . At least 90 day elapse since bone marrow transplant participant immune suppression ≥ 2 week , applicable . Adequate renal function define glomerular filtration rate ≥ 60 cc/min/1.73m^2 serum creatinine base age follow : If age 1 2 year , maximum serum creatinine ( mg/dL ) 0.6 male female . If age 2 6 year , maximum serum creatinine ( mg/dL ) 0.8 male female . If age 6 10 year , maximum serum creatinine ( mg/dL ) 1 male female . If age 10 &lt; 13 year , maximum serum creatinine ( mg/dL ) 1.2 male female . If age 13 16 year , maximum serum creatinine ( mg/dl ) 1.5 male 1.4 female . If age &gt; 16 year , maximum serum creatinine ( mg/dl ) 1.7 male 1.4 female . Adequate hepatic function define : Direct bilirubin ≤ 1.4 mg/dL ( total bilirubin &gt; 1.4 mg/dL ) AND AST ALT &lt; 5 x ULN age . Adequate cardiac function define shorten fraction ≥ 27 % ejection fraction ≥ 45 % . Lymphoma participant without bone marrow involvement must : Absolute neutrophil count ( ANC ) &gt; 1,000/mm3 , AND Platelet count ≥50,000/mm^3 ( without transfusion support ) NOTE : These criterion waive participant leukemia lymphoma participant bone marrow involvement . Written , inform consent assent follow Institutional Review Board , NCI , FDA OHRP guideline . Prior histone deacytylases ( HDAC ) , DAC , HSP90 inhibitor valproic acid treatment cancer . Patients need valproic acid medical condition study within 5 day prior first panobinostat treatment . Impaired cardiac function clinically significant cardiac disease , history arrhythmia ( include ventricular fibrillation torsade de pointes ) , bradycardia &lt; 50 bpm , screen ECG prolong QTc uncontrolled hypertension . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption panobinostat . Patients diarrhea &gt; CTCAE grade 2 . Other concurrent severe and/or uncontrolled medical condition ( e.g. , uncontrolled diabetes active uncontrolled infection ) include abnormal laboratory value , could cause unacceptable safety risk compromise compliance protocol . Patients use medication relative risk prolong QT interval induce torsade de pointes treatment discontinue switched different medication prior start treatment . Patients receive targeted agent within 2 week within 5 halflives agent active metabolite ( whichever longer ) recover side effect therapy . Patients undergone major surgery ≤ 4 week prior start treatment recover side effect therapy . Patients know positivity human immunodeficiency virus ( HIV ) hepatitis B/C . Inability swallow capsule . Active , uncontrolled infection severe concurrent medical disease , include limited congestive heart failure , cardiac arrhythmia , psychiatric illness . Isolated extramedullary relapse ( leukemia ) isolate CNS lymphoma . Pregnant lactating ( female participant childbearing potential must negative serum urine pregnancy test require within 7 day prior start treatment ) . Male female reproductive potential agree use effective contraception method duration study treatment . Down syndrome . Inability unwillingness research participant legal guardian/representative give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>Salvage Regimen</keyword>
	<keyword>Re-Induction Therapy</keyword>
	<keyword>Multi-agent chemotherapy</keyword>
</DOC>